Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Participants With PPF
Conditions
Interventions
AP01
Placebo
Locations
152
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Mayo Clinic- Scottsdale
Scottsdale, Arizona, United States
University of Southern California
Los Angeles, California, United States
Cedars-Sinai
Los Angeles, California, United States
UCLA
Los Angeles, California, United States
Newport Native MD, Inc.
Newport Beach, California, United States
Start Date
April 3, 2024
Primary Completion Date
June 1, 2027
Completion Date
June 1, 2027
Last Updated
April 6, 2026
NCT06238622
NCT07299695
NCT07466420
NCT06241560
NCT07407543
NCT07284459
Lead Sponsor
Avalyn Pharma Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions